US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Daiichi Sankyo Co., Ltd.

24.44

+0.20000.83%

Volume:462.63K

Turnover:11.46M

Market Cap:46.84B

PE:32.91

High:25.43

Open:25.07

Low:24.43

Close:24.24

Loading ...

Overview Company News Filings

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

TAK or DSNKY: Which Is the Better Value Stock Right Now?

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo Co Q4 EPS $0.22 Up From $0.10 YoY, Sales $3.18B Up From $3.05B YoY

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients

Japanese Stocks Climb 1.2%

Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DSNKY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DSNKY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSNKY\",,,,,undefined,":{"symbol":"DSNKY","market":"US","secType":"STK","nameCN":"Daiichi Sankyo Co., Ltd.","latestPrice":24.44,"timestamp":1743710400000,"preClose":24.24,"halted":0,"volume":462633,"delay":15,"floatShares":1876450459,"shares":1916602000,"eps":0.742527,"marketStatus":"Pre-Market Trading","change":0.2,"latestTime":"04-03 16:00:00 EDT Delay","open":25.07,"high":25.43,"low":24.43,"amount":11457573.014499977,"amplitude":0.041254,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.742527,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743773400000},"marketStatusCode":1,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":24.44,"volumeRatio":1.5450383617297407},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSNKY\",,,,,undefined,":{"symbol":"DSNKY","floatShares":1876450459,"roa":"4.94%","roe":"15.29%","lyrEps":0.692127,"volumeRatio":1.5450383617297407,"shares":1916602000,"dividePrice":0.41316,"high":25.43,"amplitude":0.041254,"preClose":24.24,"low":24.43,"week52Low":22.47,"pbRate":"4.19","psRate":"3.79","week52High":42.48,"institutionHeld":0,"latestPrice":24.44,"eps":0.742527,"divideRate":0.016905,"volume":462633,"delay":15,"ttmEps":0.742527,"open":25.07,"prevYearClose":27.29,"prevWeekClose":24.45,"prevMonthClose":23.88,"prevQuarterClose":23.88,"fiveDayClose":25.02,"twentyDayClose":23.45,"sixtyDayClose":27.37,"earningDate":1745424000000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DSNKY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523958946","title":"DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523958946","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523958946?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., March 31, 2025----The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU  in combination with a fluoropyrimidine chemotherapy  and Merck’s  anti-PD-1 therapy KEYTRUDA  versus trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive  gastric or gastroesophageal junction  cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy.Gastric cancer is associated with a poor prognosis, particularly in advanced stages of the disease where the five-year survival rate is 5% to 10%.1 Current recommended first-line treatment for HER2 positive advanced gastric cancer with PD-L1 CPS ≥1 is trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab.2,3 New treatment strategies ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/destiny-gastric05-phase-3-trial-120000580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","IE00B19Z4B17.USD","ADC","DSNKY","HR","BK4225","BK4211","BK4203","BK4195","PBD","IE00B66KJ199.SGD","AEIS","BK4007","BK4080","BK4157","PFS","DSKYF","IE0031619046.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2519880380","title":"TAK or DSNKY: Which Is the Better Value Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519880380","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519880380?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:40","pubTimestamp":1741966808,"startTime":"0","endTime":"0","summary":"Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co.  and Daiichi Sankyo Co., Ltd. - Sponsored ADR . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.Currently, Takeda Pharmaceutical Co. has a Zacks Rank of #2 , while Daiichi Sankyo Co., Ltd. - Sponsored ADR has a Zacks Rank of #3 . Investors should feel comfortable knowing that TAK likely has seen a stronger improvement to its earnings outlook than DSNKY has recently. However, value investors will care about much more than just this.This article originally published on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tak-dsnky-better-value-stock-154008572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSKYF","TAK","BK4007","DSNKY"],"gpt_icon":0},{"id":"2516920633","title":"ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516920633","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516920633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer. DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU. TOKYO & BASKING RIDGE, N.J., March 03, 2025----Positive topline results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU  demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival  compared to ramucirumab and paclitaxel in patients with second-line HER2 positive  unresectable and/or metastatic gastric or gastroesophageal junction  adenocarcinoma.\"We are committed to advancing the care of patients with metastatic gastric cancer and continuing to understand the role of ENHERTU in earlier lines of treatment,\" said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology Hematology R&D, AstraZeneca. \"The results of DESTINY-Gastric04 show that second-line treatment with ENHERTU can extend surv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-demonstrated-statistically-significant-clinically-130000294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4225","HR","BK4007","BK4097","BK4203","PBD","DSKYF","OS","BK4080","DSNKY","ADC"],"gpt_icon":0},{"id":"2514321468","title":"AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2514321468","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514321468?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:15","pubTimestamp":1740748553,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichi-sankyos-enhertu-recommended-for-approval-in-eu?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichi-sankyos-enhertu-recommended-for-approval-in-eu?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2456880835.USD","LU2462157665.USD","BK4007","AZN","LU1829250122.USD","BK4156","LU2236285917.USD","LU2417539215.USD","LU0109394709.USD","BK4588","LU0320765992.SGD","BK4568","LU0889565916.HKD","BK4585","DSNKY"],"gpt_icon":0},{"id":"2514329672","title":"ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514329672","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514329672?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"Recommendation based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. TOKYO & MUNICH, February 28, 2025----Daiichi Sankyo  and AstraZeneca’s  ENHERTU  has been recommended for approval in the European Union  as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 low  or HER2 ultralow  breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.In the DESTINY-Breast06 trial, ENHERTU demonstrated a 38% reduction in the risk of disease progression or death versus chemotherapy in patients with chemotherapy-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-recommended-approval-eu-chmp-130000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSNKY","CHMP","BK4156","BK4211","BK4080","BK4195","BK4087","BK4007","BK4231","DSKYF","ORR","PBD","ADC","PFS","HR","BK4225","BK4203"],"gpt_icon":0},{"id":"2512922084","title":"TAK vs. DSNKY: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2512922084","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512922084?lang=en_us&edition=fundamental","pubTime":"2025-02-18 00:40","pubTimestamp":1739810413,"startTime":"0","endTime":"0","summary":"Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co.  and Daiichi Sankyo Co., Ltd. - Sponsored ADR . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.Takeda Pharmaceutical Co. and Daiichi Sankyo Co., Ltd. - Sponsored ADR are sporting Zacks Ranks of #2  and #3 , respectively, right now. Investors should feel comfortable knowing that TAK likely has seen a stronger improvement to its earnings outlook than DSNKY has recently. However, value investors will care about much more than just this.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tak-vs-dsnky-stock-better-164013572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSNKY","BK4007","TAK","DSKYF"],"gpt_icon":0},{"id":"2508481451","title":"Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail","url":"https://stock-news.laohu8.com/highlight/detail?id=2508481451","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508481451?lang=en_us&edition=fundamental","pubTime":"2025-02-04 15:00","pubTimestamp":1738652400,"startTime":"0","endTime":"0","summary":"Survey with 7,750 participants highlights the urgent need for more and improved access to information about breast cancer and metastatic breast cancer across Europe. Results emphasise lack of knowledge of breast cancer severity, age of diagnosis and biomarker status. MUNICH & CAMBRIDGE, England, February 04, 2025----A new survey sponsored by Daiichi Sankyo and AstraZeneca reveals that there is a need for more readily available information on breast cancer, with results revealing misconceptions and a lack of public awareness. The survey conducted across the major five European countries with 7,750 respondents found varying levels of public knowledge about breast cancer and metastatic breast cancer*.1. Recognition of challenges in breast cancer: More than one-third of respondents across all countries recognise that breast cancer has not been overcome, especially in Spain (49%) and the UK (46%) where the majority of respondents do not believe in a chance of cure.\"People should not have to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/survey-reveals-88-western-europeans-070000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4168","BK4007","BK4134","WRN","DSKYF","BK4080","DSNKY","III","ADC"],"gpt_icon":0},{"id":"2507957937","title":"Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957937","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957937?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy. Datopotamab deruxtecan approved in the U.S. and Japan for same patient population. TOKYO & MUNICH, January 31, 2025----Datopotamab deruxtecan  has been recommended for approval in the European Union  for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 negative  breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.Datopotamab deruxtecan demonstrated a favorable safety profile over chemotherapy with no new safety concerns identified. Grade 3 or higher treatment-related adverse events  occurred in 21% and 45% of patients in the datopotamab deruxtecan and chemotherapy arms, respectively. The most common grade 3 or higher TRAEs were neutropenia , stomatitis , fatigue  and anemia . In the datopotamab de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-recommended-approval-eu-130000461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHMP","BK4211","PFS","PBD","DSNKY","PR","HR","CR","ORR","BK4080","BK4231","BK4225","BK4195","BK4203","BK4161","ADC","BK4007","BK4156","BK4213","DSKYF","BK4087"],"gpt_icon":0},{"id":"2507931540","title":"Daiichi Sankyo Co Q4 EPS $0.22 Up From $0.10 YoY, Sales $3.18B Up From $3.05B YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2507931540","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507931540?lang=en_us&edition=fundamental","pubTime":"2025-01-31 15:38","pubTimestamp":1738309108,"startTime":"0","endTime":"0","summary":"Daiichi Sankyo Co (OTC:DSNKY) reported quarterly earnings of $0.22 per share. This is a 120 percent increase over earnings of $0.10 per share from the same period last year. The company reported $3.18 billion in sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/43377144/daiichi-sankyo-co-q4-eps-0-22-up-from-0-10-yoy-sales-3-18b-up-from-3-05b-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Daiichi Sankyo Co Q4 EPS $0.22 Up From $0.10 YoY, Sales $3.18B Up From $3.05B YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSNKY"],"gpt_icon":0},{"id":"2507982654","title":"Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2507982654","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507982654?lang=en_us&edition=fundamental","pubTime":"2025-01-31 12:05","pubTimestamp":1738296300,"startTime":"0","endTime":"0","summary":"TOKYO, January 31, 2025----Daiichi Sankyo Company, Ltd  has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer , effective April 1, 2025.Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative Director, President and CEO.Under Dr. Manabe’s leadership, Daiichi Sankyo’s pioneering science and technology led to the resurgence of antibody drug conjugate  development within the pharmaceutical industry, leading to three of the largest licensing deals in history along with the approvals of ENHERTU and DATROWAY, two precision cancer medicines invented with Daiichi Sankyo’s DXd ADC Technology that are changing the way that metastatic breast cancer is treated.\"I am deeply honored to be the next CEO of Daiichi Sankyo and will follow Sunao Manabe’s exceptional leadership and unwavering commitment to p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/daiichi-sankyo-appoints-hiroyuki-okuzawa-040500175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1992135472.HKD","LU2272731600.USD","GB00BDT5M118.USD","COO","ADC","BK4007","LU2211815571.USD","BK4231","CFO","LU1992135399.USD","BK4585","LU2272731782.SGD","CEO","DSNKY","BK4080","BK4588","DSKYF","BK4198"],"gpt_icon":0},{"id":"2507841229","title":"TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2507841229","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507841229?lang=en_us&edition=fundamental","pubTime":"2025-01-31 12:00","pubTimestamp":1738296000,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., January 31, 2025----The first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant DATROWAY  plus rilvegostomig or rilvegostomig monotherapy versus standard of care in patients with stage 1 adenocarcinoma non-small cell lung cancer  after complete surgical resection who are ctDNA-positive or have other high risk pathological features.\"With TROPION-Lung12, we are simultaneously deploying a novel strategy for identifying patients with lung cancer who are at an increased risk of disease recurrence after surgery and evaluating novel treatment options in the adjuvant setting, including rilvegostomig with and without DATROWAY,\" said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. \"The ambitious approach in this trial underscores our commitment to both enabling more personalized treatment decisions and delivering innovative treatment options to patients with can","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tropion-lung12-phase-3-trial-040000069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4203","DSNKY","HR","PBD","BK4231","DSKYF","BK4225","SSI","BK4007","BK4080","ADC"],"gpt_icon":0},{"id":"2507611549","title":"FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2507611549","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507611549?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:11","pubTimestamp":1738080660,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application  seeking approval for expanded use of Enhertu  for HER2-low metastatic breast cancer in the United States. The approval of the added indication has triggered a $175 million milestone payment from AstraZeneca to Daiichi Sankyo.The companies’ sBLA was seeking approval for Enhertu to treat unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting.The nod in the United States expands the approved indication of Enhertu in HER2-low metastatic breast cancer to include use in an earlier disease setting as well as in a broader patient population that includes HER2-ultralow. The drug has earlier received the FDA’s Breakthrough Therapy designation in the United States for this new indication.In three months, shares of AstraZeneca have lost 6.8% compared with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-label-azns-enhertu-161100900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2417539215.USD","BK4139","BMRN","LU2236285917.USD","CSTL","BK4231","BK4195","LU0320765992.SGD","BK4568","BK4196","BK4585","LU0109394709.USD","ADC","BK4548","IE00B7SZLL34.SGD","AZN","BK4588","BK4566","BK4211","IE00B19Z3581.USD","BK4007","ALNY","LU2462157665.USD","IE00B19Z3B42.SGD","DSKYF","IE0002270589.USD","PFS","BK4080","LU1829250122.USD","LU2456880835.USD","DSNKY","LU0889565916.HKD"],"gpt_icon":0},{"id":"2506532267","title":"AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2506532267","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506532267?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:59","pubTimestamp":1738022340,"startTime":"0","endTime":"0","summary":"AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial, which showed a 36% reduction in the risk of disease progression or death versus chemotherapy.The approval extends to adult patients with unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer, the company said.\"This new approval brings this important medicine to an earlier treatment setting and a broader patient population with HER2-expressing metastatic breast cancer,\" said Dave Fredrickson, executive vice president of AstraZeneca's oncology hematology business unit.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSNKY","LU0109394709.USD","LU2456880835.USD","LU0889565916.HKD","BK4588","LU2236285917.USD","LU0320765992.SGD","LU2462157665.USD","AZN","BK4568","BK4007","BK4585","LU1829250122.USD","LU2417539215.USD"],"gpt_icon":1},{"id":"2505693202","title":"FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2505693202","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505693202?lang=en_us&edition=fundamental","pubTime":"2025-01-22 01:54","pubTimestamp":1737482080,"startTime":"0","endTime":"0","summary":"On Friday, the U.S. Food and Drug Administration  approved AstraZeneca Plc’s  Datroway for adult patients with unresectable or metastatic hormone receptor -positive, HER2-negative  breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.The approval was based on results from theTROPION-Breast01Phase 3 trial.Read Next: AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline. The safety profile ofDatrowaywas consistent with the known profile of this medicine, with no new safety concerns identified.In theDatrowayarm, the interstitial lung disease  rate was 4.2% and the majority of events were low grade.Datrowayis a specifically engineered TROP2-directed antibody drug conjugate  discovered by Daiichi Sankyo  , and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.Price Action: AZN stock is up 2.43% at $68.22 at last check Tuesday.Charles Schwab Delivers Strong Q4: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-astrazenecas-datroway-pretreated-175440598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4211","LU0109394709.USD","PFS","DSNKY","LU2462157665.USD","BK4585","BK4225","BK4195","HR","AZN","LU0889565916.HKD","LU0320765992.SGD","LU2456880835.USD","LU2236285917.USD","BK4203","DSKYF","LU1829250122.USD","BK4080","BK4007","ADC","LU2417539215.USD","BK4588","BK4568"],"gpt_icon":1},{"id":"2504953421","title":"Japanese Stocks Climb 1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504953421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504953421?lang=en_us&edition=fundamental","pubTime":"2025-01-20 15:00","pubTimestamp":1737356400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Stocks in Japan gained Monday, as the Nikkei Stock Average increased 1.2% to 38902.50.Daiichi Sankyo Co. Ltd. was the biggest gainer during the session, surging 8.2% to Y4,417, and Taiheiyo Cement Corp. surged 4.2% to Y3,833. Fanuc Corp. rounded out the top three movers, as shares gained 4.0% to Y4,672.Nintendo Co. Ltd. posted the largest decline, falling 3.0% to Y8,901, followed by shares of Furukawa Electric Co. Ltd., which fell 2.7% to Y7,120. Shares of DeNA Co. Ltd. fell 1.6% to Y2,536.On the currency front, the yen strengthened 0.1% against the dollar to Y156.21.In the bond markets, the two-year Japanese government bond yield fell 1.09 basis point to 0.683% and the 10-year JGB yield fell 0.51 basis point to 1.202%.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4554","DSNKY","BK4007","NTDOY","FANUY","BK4011","THYCY","BK4585","BK4161","BK4085"],"gpt_icon":0},{"id":"2504428278","title":"Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2504428278","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504428278?lang=en_us&edition=fundamental","pubTime":"2025-01-20 13:36","pubTimestamp":1737351360,"startTime":"0","endTime":"0","summary":"Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway.Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.The U.S. FDA approved Datroway for certain adult patients who have previously received hormone therapy and chemotherapy to treat breast cancer that can't be removed surgically or is spreading to other parts of the body.The Japanese government approved the breast cancer drug in late December.Jefferies analysts said in a note that they had assumed a 65% chance of FDA approval, but they believe that the market was less optimistic.The analysts said investors may see the approval as a good sign for the drug's potential for triple-negative breast cancer, which is hard to treat.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSNKY","BK4007"],"gpt_icon":0},{"id":"2503582012","title":"Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH","url":"https://stock-news.laohu8.com/highlight/detail?id=2503582012","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503582012?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:00","pubTimestamp":1736784000,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., January 13, 2025----Daiichi Sankyo Company, Ltd  announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1  antibody, gatipotuzumab. Such payment by Daiichi Sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing agreement between the parties. In 2018, Daiichi Sankyo in-licensed exclusive rights to develop and commercialize gatipotuzumab worldwide as an antibody drug conjugate  from Glycotope.The anti-TA-MUC1 is the antibody contained in DS-3939, an ADC being developed by Daiichi Sankyo. DS-3939 is a specifically engineered potential first-in-class TA-MUC1 directed medicine designed using Daiichi Sankyo’s proprietary DXd ADC technology. DS-3939 is currently being evaluated in a phase 1/2 clinical trial in patients with several types of advanced solid tumors including no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/daiichi-sankyo-acquires-intellectual-property-160000039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","BK4007","DSNKY","DSKYF","BK4080","PBD","BK4231"],"gpt_icon":0},{"id":"2503326508","title":"Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503326508","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503326508?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:00","pubTimestamp":1736751600,"startTime":"0","endTime":"0","summary":"Application based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 and TROPION-PanTumor01 phase 1 trials. TOKYO & BASKING RIDGE, N.J., January 13, 2025----Daiichi Sankyo  and AstraZeneca’s  Biologics License Application  for datopotamab deruxtecan  has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  who have received prior systemic therapies, including an EGFR-directed therapy.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.\"Acquired resistance to front-line therapies and, ultimately, disease progression are unfortunate realities for most patients with advanced EGFR-mutated non-small cell lung cancer,\" said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-granted-priority-review-070000802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","IE0031619046.USD","BK4231","IE00B7SZL793.SGD","BK4211","IE00B19Z4B17.USD","IE00B66KJ199.SGD","PBD","AEIS","BK4195","DSKYF","PFS","ADC","BK4007","BK4157","BK4080","OS","DSNKY"],"gpt_icon":0},{"id":"2494186046","title":"AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2494186046","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494186046?lang=en_us&edition=fundamental","pubTime":"2024-12-26 23:19","pubTimestamp":1735226340,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that they have voluntarily withdrawn the marketing authorization application  for their antibody-drug conjugate , datopotamab deruxtecan .The MAA sought approval of Dato-DXd for treating adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer  based on the TROPION-Lung01 phase III study.The companies decided to withdraw the MAA for Dato-DXd in nonsquamous NSCLC following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.Last month, AZN and Daiichi Sankyo withdrew the biologics license application  seeking approval of Dato-DXd for the same indication in the United States and instead filed a new BLA for previously treated advanced EGFR-mutated NSCLC.Shares of AstraZeneca have decreased 1.6% in the past year against the industry’s increase of 4%.Earlier this month, the FDA granted a Breakthrough Therapy designation to Dato-DXd for previously treate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azn-daiichi-withdraw-eu-filing-151900499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2361044865.SGD","LU0225771236.USD","LU0889565916.HKD","LU1066051811.HKD","IE00B1BXHZ80.USD","DSNKY","LU0109394709.USD","LU2023250504.SGD","LU1883839398.USD","SG9999014575.USD","LU1941712264.USD","IE00B19Z3B42.SGD","LU0208291251.USD","LU0861579265.USD","LU1066053197.SGD","SG9999011175.SGD","AZN","IE00B4R5TH58.HKD","LU0965509010.AUD","LU1093756325.SGD","PFE","SG9999001440.SGD","IE0002141913.USD","LU0320765489.SGD","LU2023250843.SGD","BK4550","LU1430594728.SGD","LU1974910355.USD","DSKYF","SG9999014559.SGD","LU0170899867.USD","LU1291159041.SGD","MRK","LU1934455277.USD","IE00BLSP4452.SGD","LU0238689110.USD","IE00BN8TJ469.HKD","LU0321505439.SGD","LU1934455194.USD","SG9999001176.SGD","SG9999014567.USD","LU1023059063.AUD","LU1917777945.USD","ADC","LU0225284248.USD","SG9999014542.SGD","MAA","BK4592","IE00BBT3K403.USD","SG9999015341.SGD","LU1061106388.HKD"],"gpt_icon":1},{"id":"2493095317","title":"AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2493095317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493095317?lang=en_us&edition=fundamental","pubTime":"2024-12-24 18:10","pubTimestamp":1735035008,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) have voluntarily withdrawn the marketing authorization application in the EU for datopotamab deruxteca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichi-sankyo-have-voluntarily-withdrawn-a-dato-dxd-maa-in-eu?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichi-sankyo-have-voluntarily-withdrawn-a-dato-dxd-maa-in-eu?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","BK4156","BK4585","BK4588","LU0109394709.USD","BK4215","LU2417539215.USD","LU2456880835.USD","BK4568","MAA","BK4007","LU2236285917.USD","LU0889565916.HKD","LU1829250122.USD","LU2462157665.USD","AZN","DSNKY"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DSNKY\",params:#limit:5,,,undefined,":[{"date":"2024-07-31","symbol":"DSNKY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722412800000,"name":null,"time":"","dateTimestamp":1722398400000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-01-30","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1706590800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-07","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699333200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-07-31","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1690776000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DSNKY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DSNKY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4118,"buy":0.5882,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5882,"analysts":17,"updateTime":1740801600000}}}